Medivation, Inc entered into a merger plan with Pfizer Inc. (and subsidiary) in mid August 2016. Medivation will be absorbed into Pfizer. The boards of directors of all parties have unanimously approved the Merger Agreement. The deal is expected to close in the third or fourth quarter of 2016 and is subject to customary closing conditions and U.S. antitrust clearance.
Pfizer will acquire all the outstanding shares of common stock at [Content redacted, and available only to subscribers]Medivation is a biopharmaceutical company focused on the development of small molecule drugs to treat diseases for which there are limited treatment options. Their primary commercial product is XTANDI®. The Astellas/Medivation collaboration is also conducting investigational studies of enzalutamide in prostate cancer, advanced breast cancer and hepatocellular carcinoma.
Featured image copyright: gpontinojr and Shutterstock ID: 192125255
Sources available to LER subscribers only